WHO experts to meet on AstraZeneca shot as virus cases surge
- The vaccine was developed by AstraZeneca and the University of Oxford in Britain, where more than 11 million doses have been administered apparently without any major problems.
GENEVA: WHO safety experts prepared to meet Tuesday over the AstraZeneca coronavirus vaccine whose rollout has been halted in several European countries over blood clot fears, imperilling the pandemic fight as infection rates surge.
The three largest EU nations -- Germany, Italy and France -- joined others in suspending the shot Monday, dealing a blow to the global immunisation campaign against a disease that has killed more than 2.6 million people.
The World Health Organization, AstraZeneca, and the European Medicines Agency have insisted the shot is safe, and that there is no link between the vaccine and reported blood clots.
"We do not want people to panic and we would, for the time being, recommend that countries continue vaccinating with AstraZeneca," WHO chief scientist Soumya Swaminathan said Monday.
"So far, we do not find an association between these events and the vaccine."
WHO and EMA experts on Tuesday will separately discuss data from AstraZeneca vaccinations, and the European regulator will hold an extraordinary meeting two days later to decide on any further action.
AstraZeneca's shot, among the cheapest available, was billed as the vaccine of choice for poorer nations and the clot reports have had an impact beyond Europe.
Indonesia delayed its AstraZeneca rollout on Monday, and Venezuela announced it would not authorise the jab over fears of "complications".
The vaccine was developed by AstraZeneca and the University of Oxford in Britain, where more than 11 million doses have been administered apparently without any major problems.
Prime Minister Justin Trudeau on Monday also urged Canadians to get the AstraZeneca shot after reports of hesitancy based on the suspensions in Europe.
Comments
Comments are closed for this article.